Global Anticancer Drugs Market - by Drug Type, Cancer Type, Therapy, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017- 2023)

  • ID: 4580477
  • Report
  • Region: Global
  • 122 pages
  • Oristep Consulting
25 % OFF
until Dec 31st 2018
1 of 4
This Includes Supply Demand Scenario, Market Size, Industry Updates, Trends, Etc.

FEATURED COMPANIES

  • Amgen
  • Bayer
  • Celgene
  • Gilead
  • Johnson & Johnson
  • Otsuka
  • MORE
Cancer is a disease where abnormal cells grow and divide without any control, and thus, is one of leading causes of deaths worldwide. Anticancer drugs, also called antineoplastic drugs, are effective in the treatment of cancer disease preventing the cell proliferation of cancer tissues.

Demand Scenario:

The global anticancer drugs market was 94.5 billion USD in 2017 and will reach 139.4 billion USD by 2023 with a CAGR of 6.69% during the period.

Growth by region:

The U.S., U.K and Germany are leading the market due to developed healthcare infrastructure and government initiatives to increase public awareness. Asia – Pacific will show significant growth rate owing to increase in cancer incidences and growing population in certain economies like India, China, Japan and South Korea.

Drivers vs Constraints:

The growing awareness towards cancer diagnosis and treatment, and increasing research and development activities drive the growth of the market. However, high cost of treatment may hinder the growth of the market.

Industry Trends and Updates:

Eli Lilly acquired California-based ARMO BioScience and Montreal-based AurKa Pharma Inc.

Israeli scientists invented system to deliver cancer drugs to children using nanotechnology.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Bayer
  • Celgene
  • Gilead
  • Johnson & Johnson
  • Otsuka
  • MORE
1. Research Methodology

2. Executive Summary

3. Market Overview
3.1. Definition
3.2. Industry Value Chain Analysis
3.3. Porter's 5 Forces
3.4. Regulations

4. Market Dynamics
4.1. Introduction
4.2. Drivers
4.3. Constraints
4.4. Trends

5. Global Anticancer Drugs Market Segmentation, Forecasts and Trends - by Drug Type
5.1. Targeted Drugs
5.2. Cytotoxic Drugs
5.3. Hormonal Drugs

6. Global Anticancer Drugs Market Segmentation, Forecasts and Trends - by Cancer Type
6.1. Breast Cancer
6.2. Blood cancer
6.3. Bone marrow Cancer
6.4. Prostate Cancer
6.5. Skin Cancer
6.6. Lung Cancer
6.7. Oral Cancer
6.8. Others

7. Global Anticancer Drugs Market Segmentation, Forecasts and Trends - by Therapy
7.1. Immunotherpay
7.2. Targeted Therapy
7.3. Chemotherapy
7.4. Hormonal Therapy
7.5. Others

8. Global Anticancer Drugs Market Segmentation, Forecasts and Trends - by Region
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.2. Europe
8.2.1. UK
8.2.2. France
8.2.3. Germany
8.2.4. Italy
8.2.5. Others
8.3. Asia-Pacific
8.3.1. India
8.3.2. China
8.3.3. Japan
8.3.4. Australia
8.3.5. Others
8.4. Latin America
8.4.1. Brazil
8.4.2. Argentina
8.4.3. Mexico
8.4.4. Others
8.5. Middle East and Africa
8.5.1. South Africa
8.5.2. UAE
8.5.3. Saudi Arabia
8.5.4. Egypt
8.5.5. Others

9. Company Market Share Analysis

10. Company Profiles
10.1. Celgene
10.2. Pfizer
10.3. Novartis
10.4. Eli Lilly
10.5. Bayer
10.6. Takeda
10.7. Amgen
10.8. GlaxoSmithKline
10.9. Bristol-Myers
10.10. Roche Holding
10.11. Johnson & Johnson
10.12. Gilead
10.13. Otsuka
10.14. Teva
10.15. ARIAD
10.16. Others

11. Industry Structure
11.1. Industry M&As, Consolidations
11.2. Investment Opportunities

12. Global Anticancer Drugs Market - Road Ahead

13. Tables

14. Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Celgene
  • Pfizer
  • Novartis
  • Eli Lilly
  • Bayer
  • Takeda
  • Amgen
  • GlaxoSmithKline
  • Bristol-Myers
  • Roche Holding
  • Johnson & Johnson
  • Gilead
  • Otsuka
  • Teva
  • ARIAD
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll